Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.48 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL5312853 | 0.90 | TSHR (0.60) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Acetic Acid SCHEMBL817975 | 0.88 | TSHR (0.57) | TSHRNOTUMHSD17B3CYP2A6MAOA | |
| Carbamic Acid SCHEMBL2175348 | 0.88 | TSHR (0.57) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Propionamide SCHEMBL28815857 | 0.85 | TSHR (0.48) | TSHRNOTUMCYP2A6MAOAMAOB | |
| SCHEMBL5315114 | 0.84 | CRBN (0.52) | TSHRNOTUMHSD17B3RIPK1MTNR1A | |
| Acetic Acid SCHEMBL3435922 | 0.83 | TSHR (0.65) | TSHRNOTUMHSD17B3RIPK1MTNR1A | |
| Carbamic Acid SCHEMBL9011736 | 0.83 | TSHR (0.65) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Butanone SCHEMBL7687029 | 0.82 | TSHR (0.50) | TSHRNOTUMHSD17B3CYP2A6MAOA | |
| Methylamine SCHEMBL2462109 | 0.82 | TSHR (0.71) | TSHRCYP2A6MAOAMAOB | |
| Methyl Alcohol SCHEMBL28873001 | 0.82 | TSHR (0.71) | TSHRNOTUMCYP2A6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242066-B1 | USE OF 1-AMINOINDAN DERIVATIVES FOR TREATMENT OF MANIA IN BIPOLAR MOOD DISORDER | TEVA PHARMA (IL) | 2006-06-28 | — | — | EP | claimed |
| US-20070238895-A1 | N-protected aminoindanes and methods of their preparation | TEVA PHARMACEUTICALS USA, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007056455-A2 | N-PROTECTED AMINOINDANES AND METHODS OF THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-05-18 | — | — | WO | disclosed |
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | disclosed |
| US-6528685-B2 | Such as (R)-N-(2-acetamido)-1-aminoindan for treatment of Parkinson's disease, dementia, epilepsy, convulsions, or seizures | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-03-04 | — | — | US | disclosed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | disclosed |
| US-6271263-B1 | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2001-08-07 | — | — | US | disclosed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | disclosed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | disclosed |
| US-5914349-A | ANTICONVULSANTS, EPILEPSY AND COGNITIVE AGENTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-06-22 | — | — | US | disclosed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | disclosed |
| US-5877218-A | PARKINSON'S DISEASE; ANTIEPILEPSY AGENTS; ANTICONVULSANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5639913-A | TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-06-17 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238895-A1 | N-protected aminoindanes and methods of their preparation | PNMT, HNMT, NLN | TSHR 3685/4885NOTUM 902/4885HSD17B3 3739/4885 |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | PARK7, GAP43, PSEN1 | TSHR 4794/4885NOTUM 1766/4885HSD17B3 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.